 reuters    u s  lawmakers on tuesday approved a bill to provide financial incentives to companies developing treatments for the zika virus  and the white house said president barack obama was expected to sign the legislation although it is insufficient to meet the challenge  the measure allows the food and drug administration to include zika drug developers in the agency s priority review voucher program  the program encourages manufacturers to study treatments for diseases that might not be profitable by expediting the regulatory review of a more lucrative drug in their research pipeline  the house of representatives passed the bill on a voice vote  without a roll call  weeks after the same measure was approved by the senate  white house spokeswoman katie hill said obama was expected to sign the bill  which she called a  small step  that could encourage the private sector to tackle zika   but it contains no funding and is ultimately insufficient on its own  since it doesn t provide the    billion in funding that our public health experts have said is needed right now to prepare americans for the imminent local transmission of zika in this country   she said in a statement  democrats and administration officials are urging the republican controlled congress to grant nearly    billion in emergency funds to combat the spread of zika  in a temporary fix  the white house said last week that it would redirect   million in allocated funds to prepare for the mosquito that carries the disease to emerge in the continental united states  according to the world health organization  there is a strong scientific consensus that the zika virus can cause the rare birth defect microcephaly in newborns  but the link between the virus and the birth defects has not been scientifically established  on tuesday  brazil confirmed   cases of microcephaly and considers most to be related to zika infections in the mother  drugmakers who are working on zika related drugs  or considering such research  include sanofi sa  glaxosmithkline plc  inovio pharmaceuticals inc and takeda pharmaceutical co ltd   zika was first detected in brazil last year and is spreading through the americas  the world health organization had declared a global health emergency due to the virus s possible link to microcephaly in babies and guillain barre syndrome  a rare neurological disorder  in adults  on monday  top health officials said the mosquito that spreads the virus is now present in about  u s  states  making local outbreaks a possibility  they have also predicted hundreds of thousands of people would be infected in puerto rico when the mosquito season kicks in this summer  a pharmaceutical company may be given a priority review voucher to develop a drug for an infectious disease  in this case zika  which may not generate much profit for the manufacturer  the voucher gives the company the right to an accelerated review by the fda of any other  more lucrative  drug in its pipeline  developing a new drug can take years and cost millions of dollars  a standard fda review takes at least  months to complete   longer if the agency requires additional information  being able to shave time off that process and get a profitable drug onto the market faster can be worth millions of dollars to a manufacturer  under the agency s priority review program  companies who submit a drug for review that is intended to treat serious conditions or whose drug shows a significant improvement in safety or effectiveness over existing treatments is eligible to be reviewed in six months  at least four months faster than usual  a priority review voucher gives a company the right to a six month review on any product  regardless of whether it meets the conditions normally required to receive an accelerated review  it also gives the company the right to sell the voucher to another company  the law currently makes any company eligible for a priority review voucher that is developing a drug for one of more than  tropical diseases listed under the voucher program  these include malaria  cholera  leprosy  dengue  tuberculosis  and ebola  the fda has the authority to add other infectious diseases to the list which primarily affects poor countries  